NLX-112

· Neurolixis SAS

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NLX-112, covering 2024-04-23 to 2024-04-23. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia [Phase 2]

See pricing